본문 바로가기
KERD
논문KCI 등재

Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Oral Combination Treatment of Tamoxifen 50 mg/kg with JEKHT 100 mg/kg on JEKHT 6-day Repeated Pretreated Rats with 8-day Repeated Co-administration

이영준|구세광|박수진|곽민아|박성환
대한예방한의학회 (Society of Preventive Korean Medicine)|2016.08|대한예방한의학회지 (Society of Preventive Korean Medicine)|제20권 제2호|pp. 97-109

2

조회

0

다운로드

5

인용

0

참고문헌

키워드

PharmacokineticsDrug-drug interactionsTamoxifenJaeumkanghwatangRepeat oral doseRepeated JEKHT pretreatment
주제분류한의학

초록

Objectives: The effects of Jaeumkanghwatang (JEKHT) co-administration on the pharmacokinetics of tamoxifen were observed after oral combination treatment of tamoxifen 50 mg/kg with JEKHT 100 mg/kg on JEKHT 6-day repeated oral pretreated rats with 8-day repeated co-administration to confirm the effects of JEKHT co-administration on the pharmacokinetics of tamoxifen. Methods: Six days after pretreatment of JEKHT 100 mg/kg, tamoxifen 50 mg/kg was co-administered with JEKHT 100 mg/kg, once a day for 8 days within 5 min. The blood were collected at 30 min before administration, 30 min, 1, 2, 3, 4, 6, 8 and 24 hrs after end of first and last 8th tamoxifen treatment, and plasma concentrations of tamoxifen were analyzed using LC-MS/MS methods. PK parameters of tamoxifen (Tmax, Cmax, AUC, t1/2 and MRTinf) were analysis as compared with tamoxifen single administered. Results: Six-day repeated oral pretreatment of JEKHT and 8-day repeated oral co-administration of tamoxifen within 5 min did not influenced on the plasma concentrations and pharmacokinetic parameters of tamoxifen, oral bioavailability, as compared with tamoxifen single treated rats, except for some negligible effects. Conclusions: It is concluded that JEKHT did not influenced on the plasma concentrations and pharmacokinetic parameters, the oral bioavailability of tamoxifen. Therefore, it is considered that co-administration of JEKHT and tamoxifen will be provide an effective novel treatment regimen on the comprehensive and integrative medicine for breast cancer patients, if they showed favorable synergic effects on the pharmacodynamics or reduce the tamoxifen treatment related toxicity and side effects in future studies.

Abstract

Objectives: The effects of Jaeumkanghwatang (JEKHT) co-administration on the pharmacokinetics of tamoxifen were observed after oral combination treatment of tamoxifen 50 mg/kg with JEKHT 100 mg/kg on JEKHT 6-day repeated oral pretreated rats with 8-day repeated co-administration to confirm the effects of JEKHT co-administration on the pharmacokinetics of tamoxifen. Methods: Six days after pretreatment of JEKHT 100 mg/kg, tamoxifen 50 mg/kg was co-administered with JEKHT 100 mg/kg, once a day for 8 days within 5 min. The blood were collected at 30 min before administration, 30 min, 1, 2, 3, 4, 6, 8 and 24 hrs after end of first and last 8th tamoxifen treatment, and plasma concentrations of tamoxifen were analyzed using LC-MS/MS methods. PK parameters of tamoxifen (Tmax, Cmax, AUC, t1/2 and MRTinf) were analysis as compared with tamoxifen single administered. Results: Six-day repeated oral pretreatment of JEKHT and 8-day repeated oral co-administration of tamoxifen within 5 min did not influenced on the plasma concentrations and pharmacokinetic parameters of tamoxifen, oral bioavailability, as compared with tamoxifen single treated rats, except for some negligible effects. Conclusions: It is concluded that JEKHT did not influenced on the plasma concentrations and pharmacokinetic parameters, the oral bioavailability of tamoxifen. Therefore, it is considered that co-administration of JEKHT and tamoxifen will be provide an effective novel treatment regimen on the comprehensive and integrative medicine for breast cancer patients, if they showed favorable synergic effects on the pharmacodynamics or reduce the tamoxifen treatment related toxicity and side effects in future studies.

참고문헌 (45)

  1. Kim SY, "a-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes", Chem Res Toxicol, 16(9), pp.1138~1144 (2003)
  2. Notley LM, "Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its a-hydroxy and a, 4-dihydroxy derivatives", Chem Res Toxicol, 18(10), pp.1611~1618 (2005)
  3. Lien EA, "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide", Cancer Res, 50(18), pp.5851~5857 (1990)
  4. Ritchie LD, "Tamoxifen-warfarin interaction : the Aberdeen hospitals drug file", BMJ, 298(6682), pp.1253~ (1989)
  5. Tenni P, "Life threatening interaction between tamoxifen and warfarin", BMJ, 298(6666), pp.93~ (1989)
  6. Lamberts SW, "Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells", J Clin Endocrinol Metab, 63(6), pp.1342~1347 (1986)
  7. Dowsett M, "Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer", Clin Cancer Res, 5(9), pp.2338~2343 (1999)
  8. Reid AD, "Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients", Breast Cancer Res Treat, 22(2), pp.153~156 (1992)
  9. Dehal SS, "The aromatase inactivator 4-hydroxyandrostenedione(4-OH-A)inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A : potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy", Drug Metab Dispos, 27(3), pp.389~394 (1999)
  10. West CM, "Additive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells", Cancer Lett, 55(2), pp.159~163 (1990)
  11. Mani C, "Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation", Drug Metab Dispos, 21(4), pp.645~656 (1993)
  12. Mani C, "Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes", Carcinogenesis, 15(12), pp.2715~2720 (1994)
  13. Williams JA, "Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7", Drug Metab Dispos, 30(8), pp.883~891 (2002)
  14. 정다영, "대표적인 補陰之劑의 면역 활성화 비교 연구- 육미지황탕, 자음강화탕, 쌍화탕 -", 대한한의학회지, 31(5), pp.112~123 (2010), 대한한의학회
  15. Sekiya N, "Experimental Application of Jiin-koka-to to Cases of Bronchial Asthma", Kampo Medicine, 54(6), pp.1097~1101 (2003)
  16. 김유경, "자음강화탕의 알레르기성 영증반응억제 효과", 대한한방내과학회지, 25(2), pp.174~182 (2004), 대한한방내과학회
  17. 정홍매, "자음강화탕 투여 후 상열감의 호전을 보인 타목시펜 복용 중인 유방암 환자 1례", 대한한방내과학회지, 31(2), pp.395~400 (2010), 대한한방내과학회
  18. 곽민아, "Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (1) - Single Oral Combination Treatment of Tamoxifen 50mg", kg with JEKHT 100 mg, 대한한의학회지, pp.2016, 37(2)[DOI]
  19. Gibaldi M, "Pharmacokinetics" (1982), Taylor & Francis
  20. Bailer AJ, "Testing for the equality of area under the curves when using destructive measurement techniques", J Pharmacokinet Biopharm, 16(3), pp.303~309 (1988)
  21. Chiou WL, "Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve", J Pharmacokinet Biopharm, 6(6), pp.539~546 (1978)
  22. Fox JG, "Laboratory Animal Medicine" (1984), Academic Press. Inc
  23. Tajima Y, "Biological reference data book on experimental animals" (1989), Soft Science
  24. Adam HK, "Measurement of tamoxifen in serum by thin-layer densitometry", J Endocrinol, 84(1), pp.35~42 (1980)
  25. Adam HK, "Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers", Cancer Treat Rep, 64(6-7), pp.761~764 (1980)
  26. Fabian C, "Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules", Cancer Treat Rep, 64(6-7), pp.765~773 (1980)
  27. Jordan VC, "Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer", Cancer Res, 43(3), pp.1446~1450 (1983)
  28. Murphy C, "Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry(GC-MS)using selected ion monitoring(SIM)", J Steroid Biochem, 26(5), pp.547~555 (1987)
  29. Jordan VC, "Metabolites of tamoxifen in animals and man : identification, pharmacology, and significance", Breast Cancer Res Treat, 2(2), pp.123~138 (1982)
  30. Sun D, "Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases", Drug Metab Dispos, 35(11), pp.2006~2014 (2007)
  31. AstraZeneca Pharmaceuticals, "Nolvadex (tamoxifen citrate) prescribing information", ~ (2003)
  32. Hall WA, "Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas", J Neurooncol, 77(3), pp.279~284 (2006)
  33. Vehmanen L, "Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status", J Clin Oncol, 24(4), pp.675~680 (2006)
  34. Grilli S, "Tamoxifen(TAM) : the dispute goes on", Ann Ist Super Sanita, 42(2), pp.170~173 (2006)
  35. Decensi A, "Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial", Circulation, 111(5), pp.650~656 (2005)
  36. Osman KA, "Tamoxifen-induced non-alcoholic steatohepatitis:where are we now and where are we going?", Expert Opin Drug Saf, 6(1), pp.1~4 (2007)
  37. Paganini-Hill A, "Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen", Breast Cancer Res Treat, 64(2), pp.165~176 (2000)
  38. Eberling JL, "Estrogen-and tamoxifen-associated effects on brain structure and function", Neuroimage, 21(1), pp.364~371 (2004)
  39. Mortimer JE, "Effect of tamoxifen on sexual functioning in patients with breast cancer", J Clin Oncol, 17(5), pp.1488~1492 (1999)
  40. Cella D, "Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination)trial after completion of 5 years’adjuvant treatment for early breast cancer", Breast Cancer Res Treat, 100(3), pp.273~284 (2006)
  41. Karimian E, "Tamoxifen impairs both longitudinal and cortical bone growth in young male rats", J Bone Miner Res, 23(8), pp.1267~1277 (2008)
  42. Wilson SC, "Evidence for the involvement of central conversion of testosterone to oestradiol-17b in the regulation of luteinizing hormone secretion in the cockerel", J Endocrinol, 99(2), pp.301~310 (1983)
  43. Nalbandian G, "The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation", J Immunol, 175(4), pp.2666~2675 (2005)
  44. Berstein LM, "Long-term exposure to tamoxifen induces hypersensitivity toestradiol", Clin Cancer Res, 10(4), pp.1530~1534 (2004)
  45. Rousset-Jablonski C, "Tamoxifen contraindicated in women with hereditary angioedema?", Ann Oncol, 20(7), pp.1281~1282 (2009)

관련 논문AI추천

Effect of Gamiondam-tang (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Single Oral Combination Treatment of Tamoxifen 50 mg/kg with GMODT 100 mg/kg with 2.5 hr-intervals -강수진, 구세광, 류은아, 송창현, 이봉효, 이영준, 최성훈, 한창현대한예방한의학회 · 대한예방한의학회지2017 · 제21권 제2호Effect of the Single Oral Combination Treatment of Tamoxifen with Gamisoyo-san on the Pharmacokinetics Profiles of Tamoxifen구세광, 김주익, 이영준한의병리학회 · 동의생리병리학회지2020 · 제34권 제4호Effect of Gongjindan, a Polyherbal Formula on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (1) - Single Oral Combination Treatment of Sorafenib 50mg/kg with Gongjindan 100mg/kg within 5min -강수진, 구세광, 김승모, 박수진, 송창현, 이영준, 이창형, 한창현대한예방한의학회 · 대한예방한의학회지2014 · 제18권 제2호Effect of Gongjindan-gamibang on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (2) - Single Oral Combination Treatment of Sorafenib 50mg/kg with Gongjindan-gamibang 100 mg/kg, 3.5hr-intervals with 7-day Repeated Treatment -강수진, 구세광, 김승모, 박수진, 송창현, 이영준, 이창형, 한창현대한예방한의학회 · 대한예방한의학회지2015 · 제19권 제1호Effect of Gongjindon a Traditional Korean Polyherbal Formula, on the Pharmacokinetics Profiles of Donepezil in Male SDRats (1) -Single Oral Combination Treatment of Donepezil 10mg/kg with Gongjindan 100mg/kg within 5 min -구세광, 권오대, 박수진, 이영준, 정대규대한예방한의학회 · 대한예방한의학회지2013 · 제17권 제1호Effect of Gongjindan, a Traditional Korean Polyherbal Formula, on the Pharmacokinetics Profiles of Donepezil in Male SDRats (2) ― Single Oral Combination Treatment of Donepezil 10mg/kg with Gongjindan 100mg/kg, 1.5hr-intervals with 7-day Repeated Treatment ―구세광, 권오대, 박수진, 이영준, 정대규대한예방한의학회 · 대한예방한의학회지2013 · 제17권 제2호

이 간행물의 다른 논문 (8건)

한의약 분야의 2040년 델파이 기술예측조사 연구안미영, 김동준, 김동수, 우종민, 권영규, 권수현, 정근하, 구기훈, 허신희pp. 1-15건강 증진을 위한 평소 증상 기반의 한열변증 설문지 개발 - 일치도를 중심으로이시우, 여민경, 이영섭, 배광호, 윤영흠, 김호석pp. 17-26대만 중의 건강보험의 체계와 서비스 질 향상 정책임병묵, 권수현, 김동수, 정설희, 안보령pp. 27-38한의대생의 휴학경험에 관한 현상학적 연구신헌태, 안효자pp. 39-51한의과대학생의 유급경험에 관한 현상학적 연구신헌태pp. 53-67
원문 보기